Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Benzyloxycarbonyl-proline-prolinal (ZPP): Dual complementary roles for neutrophil inhibition.

Russell DW, Hardison M, Genschmer KR, Szul T, Bratcher PE, Abdul Roda M, Xu X, Viera L, Blalock JE, Gaggar A, Noerager BD.

Biochem Biophys Res Commun. 2019 Aug 7. pii: S0006-291X(19)31479-2. doi: 10.1016/j.bbrc.2019.07.111. [Epub ahead of print]

PMID:
31400851
2.

Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: a biomarker for functional cure.

Walsh R, Hammond R, Yuen L, Deerain J, O'Donnell T, Leary T, Cloherty G, Gaggar A, Kitrinos K, Subramanian M, Wong D, Locarnini S.

Liver Int. 2019 Aug 4. doi: 10.1111/liv.14207. [Epub ahead of print]

PMID:
31379058
3.

Long-Term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients with Chronic HCV Infection.

Younossi ZM, Stepanova M, Racila A, Afendy A, Lawitz EJ, Schwabe C, Ruane PJ, Lalezari J, Reddy KR, Jacobson IM, Muir AJ, Gaggar A, Myers RP, Younossi I, Nader F.

Clin Gastroenterol Hepatol. 2019 Jul 31. pii: S1542-3565(19)30836-5. doi: 10.1016/j.cgh.2019.07.047. [Epub ahead of print]

PMID:
31376493
4.

Genomic modeling of hepatitis B virus integration frequency in the human genome.

Podlaha O, Wu G, Downie B, Ramamurthy R, Gaggar A, Subramanian M, Ye Z, Jiang Z.

PLoS One. 2019 Jul 29;14(7):e0220376. doi: 10.1371/journal.pone.0220376. eCollection 2019.

5.

Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients.

Podlaha O, Gane E, Brunetto M, Fung S, Chuang WL, Pan CQ, Jiang Z, Liu Y, Bhardwaj N, Mukherjee P, Flaherty J, Gaggar A, Subramanian M, Izumi N, Shalimar, Lim YS, Marcellin P, Buti M, Chan HLY, Agarwal K.

Sci Rep. 2019 Jul 19;9(1):10529. doi: 10.1038/s41598-019-46609-7.

6.

Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study.

Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, Schwabe C, Dunbar PR.

J Hepatol. 2019 Jul 12. pii: S0168-8278(19)30400-3. doi: 10.1016/j.jhep.2019.06.028. [Epub ahead of print]

PMID:
31306680
7.

Induced pluripotent stem cell-derived endothelial cells attenuate lipopolysaccharide-induced acute lung injury.

Xing D, Wells JM, Giordano SS, Feng W, Gaggar A, Yan J, Hage FG, Li L, Chen YF, Oparil S.

J Appl Physiol (1985). 2019 Aug 1;127(2):444-456. doi: 10.1152/japplphysiol.00587.2018. Epub 2019 Jul 11.

PMID:
31295064
8.

Response to Comment on "An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness".

Patel DF, Gaggar A, Blalock JE, Gregory LG, Lloyd CM, Snelgrove RJ.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaaw0462. doi: 10.1126/scitranslmed.aaw0462.

PMID:
31217333
9.

Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis.

Turnbull AR, Pyle CJ, Patel DF, Jackson PL, Hilliard TN, Regamey N, Tan HL, Brown S, Thursfield R, Short C, Mc Fie M, Alton EWFW, Gaggar A, Blalock JE, Lloyd CM, Bush A, Davies JC, Snelgrove RJ.

J Cyst Fibros. 2019 Jun 5. pii: S1569-1993(19)30769-6. doi: 10.1016/j.jcf.2019.05.017. [Epub ahead of print]

10.

Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.

Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M.

Liver Int. 2019 May 28. doi: 10.1111/liv.14155. [Epub ahead of print]

PMID:
31136052
11.

Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.

Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Liaw YF, Hansen BE, Choi H, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Knegt RJ, Janssen HLA.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):538-544. doi: 10.1016/S2468-1253(19)30087-1. Epub 2019 Apr 9.

PMID:
30975477
12.

Proline-Glycine-Proline Peptides Are Critical in the Development of Smoke-Induced Emphysema.

Abdul Roda M, Xu X, Abdalla TH, Sadik M, Szul T, Bratcher PE, Viera L, Solomon GM, Wells JM, McNicholas CM, Redegeld FA, Folkerts G, Blalock JE, Gaggar A.

Am J Respir Cell Mol Biol. 2019 Apr 8. doi: 10.1165/rcmb.2018-0216OC. [Epub ahead of print]

PMID:
30958968
13.

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C.

Gastroenterology. 2019 Jul;157(1):227-241.e7. doi: 10.1053/j.gastro.2019.03.044. Epub 2019 Mar 28.

PMID:
30930022
14.

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P.

Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.

PMID:
30795958
15.

Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial.

Tangpricha V, Lukemire J, Chen Y, Binongo JNG, Judd SE, Michalski ES, Lee MJ, Walker S, Ziegler TR, Tirouvanziam R, Zughaier SM, Chesdachai S, Hermes WA, Chmiel JF, Grossmann RE, Gaggar A, Joseph PM, Alvarez JA.

Am J Clin Nutr. 2019 Mar 1;109(3):544-553. doi: 10.1093/ajcn/nqy291.

PMID:
30793177
16.

A cleft lip and palate gene, Irf6, is involved in osteoblast differentiation of craniofacial bone.

Thompson J, Mendoza F, Tan E, Bertol JW, Gaggar AS, Jun G, Biguetti C, Fakhouri WD.

Dev Dyn. 2019 Mar;248(3):221-232. doi: 10.1002/dvdy.13. Epub 2019 Feb 7.

PMID:
30684382
17.

What Lies beneath: Preformed Autoantibodies and Lung Transplantation.

Duncan SR, Gaggar A.

Am J Respir Cell Mol Biol. 2019 Jun;60(6):613-614. doi: 10.1165/rcmb.2018-0415ED. No abstract available.

18.

Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung.

Genschmer KR, Russell DW, Lal C, Szul T, Bratcher PE, Noerager BD, Abdul Roda M, Xu X, Rezonzew G, Viera L, Dobosh BS, Margaroli C, Abdalla TH, King RW, McNicholas CM, Wells JM, Dransfield MT, Tirouvanziam R, Gaggar A, Blalock JE.

Cell. 2019 Jan 10;176(1-2):113-126.e15. doi: 10.1016/j.cell.2018.12.002.

PMID:
30633902
19.

Discovery of half-life of circulating HBsAg in patients with chronic hepatitis B infection using heavy water labeling.

Loomba R, Decaris M, Li KW, Shankaran M, Mohammed H, Matthews M, Richards LM, Nguyen P, Rizo E, Andrews B, Soto R, Angel T, Suri V, Kitrinos KM, Barnes D, Czerwieniec G, Brendza K, Subramanian GM, Gaggar A, Hellerstein MK.

Clin Infect Dis. 2018 Dec 24. doi: 10.1093/cid/ciy1100. [Epub ahead of print]

PMID:
30590481
20.

Gene expression profiling of human tissue-resident immune cells: Comparing blood and liver.

Boeijen LL, van Oord GW, Hou J, van der Heide-Mulder M, Gaggar A, Li L, Fletcher SP, de Knegt RJ, Boonstra A.

J Leukoc Biol. 2019 Mar;105(3):603-608. doi: 10.1002/JLB.6AB0718-278R. Epub 2018 Nov 27.

PMID:
30480838
21.

Differences among cigarette-only smokers compared to dual users of cigarettes and little cigars/cigarillos in the criminal justice population.

Schiavon S, Hodgin K, Sellers A, Hendricks PS, Gaggar A, Scarinci I, Cropsey KL.

Addict Behav. 2019 Mar;90:236-240. doi: 10.1016/j.addbeh.2018.11.001. Epub 2018 Nov 8.

PMID:
30458372
22.

Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene.

Wells JM, Parker MM, Oster RA, Bowler RP, Dransfield MT, Bhatt SP, Cho MH, Kim V, Curtis JL, Martinez FJ, Paine R 3rd, O'Neal W, Labaki WW, Kaner RJ, Barjaktarevic I, Han MK, Silverman EK, Crapo JD, Barr RG, Woodruff P, Castaldi PJ, Gaggar A, Investigators TSAC.

JCI Insight. 2018 Nov 15;3(22). pii: 123614. doi: 10.1172/jci.insight.123614.

23.

An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness.

Patel DF, Peiró T, Shoemark A, Akthar S, Walker SA, Grabiec AM, Jackson PL, Hussell T, Gaggar A, Xu X, Trevor JL, Li J, Steele C, Tavernier G, Blalock JE, Niven RM, Gregory LG, Simpson A, Lloyd CM, Snelgrove RJ.

Sci Transl Med. 2018 Aug 22;10(455). pii: eaaq0693. doi: 10.1126/scitranslmed.aaq0693.

24.

Early airway microbial metagenomic and metabolomic signatures are associated with development of severe bronchopulmonary dysplasia.

Lal CV, Kandasamy J, Dolma K, Ramani M, Kumar R, Wilson L, Aghai Z, Barnes S, Blalock JE, Gaggar A, Bhandari V, Ambalavanan N.

Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L810-L815. doi: 10.1152/ajplung.00085.2018. Epub 2018 Aug 16.

PMID:
30113227
25.

The neutrophil chemoattractant peptide proline-glycine-proline is associated with acute respiratory distress syndrome.

Sharma NS, Lal CV, Li JD, Lou XY, Viera L, Abdallah T, King RW, Sethi J, Kanagarajah P, Restrepo-Jaramillo R, Sales-Conniff A, Wei S, Jackson PL, Blalock JE, Gaggar A, Xu X.

Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L653-L661. doi: 10.1152/ajplung.00308.2017. Epub 2018 Aug 9.

PMID:
30091378
26.

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.

Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01064-18. doi: 10.1128/AAC.01064-18. Print 2018 Oct.

27.

ADAM9: A Damaging Player in Chronic Obstructive Pulmonary Disease.

Russell DW, Gaggar A.

Am J Respir Crit Care Med. 2018 Dec 15;198(12):1465-1466. doi: 10.1164/rccm.201805-1012ED. No abstract available.

PMID:
29986153
28.

Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.

Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, Tabak F, Nguyen TT, Chuang WL, Inokuma T, Ikeda F, Santantonio TA, Habersetzer F, Ramji A, Lau AH, Suri V, Flaherty JF, Wang H, Gaggar A, Subramanian GM, Mukewar S, Brunetto MR, Fung S, Chan HL.

Clin Gastroenterol Hepatol. 2018 Jun 20. pii: S1542-3565(18)30633-5. doi: 10.1016/j.cgh.2018.06.023. [Epub ahead of print]

PMID:
29933096
29.

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis.

De Rose V, Burgel PR, Gaggar A, Greene C.

Mediators Inflamm. 2018 May 2;2018:7280747. doi: 10.1155/2018/7280747. eCollection 2018. No abstract available.

30.

Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.

Agarwal K, Ahn SH, Elkhashab M, Lau AH, Gaggar A, Bulusu A, Tian X, Cathcart AL, Woo J, Subramanian GM, Andreone P, Kim HJ, Chuang WL, Nguyen MH.

J Viral Hepat. 2018 Nov;25(11):1331-1340. doi: 10.1111/jvh.12942. Epub 2018 Aug 22.

PMID:
29851204
31.

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators.

J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17.

PMID:
29756595
32.

Fibroblast growth factor 23 and Klotho contribute to airway inflammation.

Krick S, Grabner A, Baumlin N, Yanucil C, Helton S, Grosche A, Sailland J, Geraghty P, Viera L, Russell DW, Wells JM, Xu X, Gaggar A, Barnes J, King GD, Campos M, Faul C, Salathe M.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800236. doi: 10.1183/13993003.00236-2018. Print 2018 Jul.

33.

Frontline Science: Pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis.

Forrest OA, Ingersoll SA, Preininger MK, Laval J, Limoli DH, Brown MR, Lee FE, Bedi B, Sadikot RT, Goldberg JB, Tangpricha V, Gaggar A, Tirouvanziam R.

J Leukoc Biol. 2018 Oct;104(4):665-675. doi: 10.1002/JLB.5HI1117-454RR. Epub 2018 May 9.

PMID:
29741792
34.

An OX40/OX40L interaction directs successful immunity to hepatitis B virus.

Publicover J, Gaggar A, Jespersen JM, Halac U, Johnson AJ, Goodsell A, Avanesyan L, Nishimura SL, Holdorf M, Mansfield KG, Judge JB, Koshti A, Croft M, Wakil AE, Rosenthal P, Pai E, Cooper S, Baron JL.

Sci Transl Med. 2018 Mar 21;10(433). pii: eaah5766. doi: 10.1126/scitranslmed.aah5766.

35.

Exosomal microRNA predicts and protects against severe bronchopulmonary dysplasia in extremely premature infants.

Lal CV, Olave N, Travers C, Rezonzew G, Dolma K, Simpson A, Halloran B, Aghai Z, Das P, Sharma N, Xu X, Genschmer K, Russell D, Szul T, Yi N, Blalock JE, Gaggar A, Bhandari V, Ambalavanan N.

JCI Insight. 2018 Mar 8;3(5). pii: 93994. doi: 10.1172/jci.insight.93994.

36.

Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.

Garcia BA, Carden JL, Goodwin DL, Smith TA, Gaggar A, Leon K, Antony VB, Rowe SM, Solomon GM.

BMC Pulm Med. 2018 Feb 14;18(1):35. doi: 10.1186/s12890-018-0594-8.

37.

ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.

Wong D, Littlejohn M, Edwards R, Jackson K, Revill P, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti-Ferret M, Janssen H, Gane E, Locarnini S, Thompson A.

Liver Int. 2018 Oct;38(10):1760-1769. doi: 10.1111/liv.13716. Epub 2018 Mar 6.

PMID:
29427368
38.

TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C.

Gastroenterology. 2018 May;154(6):1764-1777.e7. doi: 10.1053/j.gastro.2018.01.030. Epub 2018 Jan 31.

PMID:
29378197
39.

Systemic Markers of Adaptive and Innate Immunity Are Associated with Chronic Obstructive Pulmonary Disease Severity and Spirometric Disease Progression.

Halper-Stromberg E, Yun JH, Parker MM, Singer RT, Gaggar A, Silverman EK, Leach S, Bowler RP, Castaldi PJ.

Am J Respir Cell Mol Biol. 2018 Apr;58(4):500-509. doi: 10.1165/rcmb.2017-0373OC.

40.

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.

Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ.

J Hepatol. 2018 Mar;68(3):431-440. doi: 10.1016/j.jhep.2017.10.027. Epub 2017 Dec 11.

PMID:
29104121
41.

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.

Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA.

Aliment Pharmacol Ther. 2018 Jan;47(1):114-122. doi: 10.1111/apt.14362. Epub 2017 Oct 11.

42.

Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma.

Estevez J, Chen VL, Podlaha O, Li B, Le A, Vutien P, Chang ET, Rosenberg-Hasson Y, Jiang Z, Pflanz S, Ge D, Gaggar A, Nguyen MH.

Sci Rep. 2017 Sep 19;7(1):11867. doi: 10.1038/s41598-017-11975-7.

43.

Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers.

Chen VL, Le AK, Podlaha O, Estevez J, Li B, Vutien P, Chang ET, Rosenberg-Hasson Y, Pflanz S, Jiang Z, Ge D, Gaggar A, Nguyen MH.

Sci Rep. 2017 Sep 11;7(1):11169. doi: 10.1038/s41598-017-10498-5.

44.

Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance.

Grossi G, Loglio A, Facchetti F, Borghi M, Soffredini R, Galmozzi E, Lunghi G, Gaggar A, Lampertico P.

J Hepatol. 2017 Sep 21. pii: S0168-8278(17)32260-2. doi: 10.1016/j.jhep.2017.08.020. [Epub ahead of print]

PMID:
28870666
45.

The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection.

Payne GA, Li J, Xu X, Jackson P, Qin H, Pollock DM, Wells JM, Oparil S, Leesar M, Patel RP, Blalock JE, Gaggar A.

Sci Rep. 2017 Aug 8;7(1):7563. doi: 10.1038/s41598-017-07610-0.

46.

The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis.

Tangpricha V, Smith EM, Binongo J, Judd SE, Ziegler TR, Walker S, Tirouvanziam R, Zughaier SM, Lee MJ, Chesdachai S, Hermes WA, Chmiel JF, Gaggar A, Grossmann RE, Joseph PM, Alvarez JA.

Contemp Clin Trials Commun. 2017 Jun;6:39-45. doi: 10.1016/j.conctc.2017.02.010. Epub 2017 Mar 9.

47.

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. Erratum in: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2.

PMID:
28404092
48.

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K; GS-US-320-0110 Investigators.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. doi: 10.1016/S2468-1253(16)30024-3. Epub 2016 Sep 22. Erratum in: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2.

PMID:
28404091
49.

Doxycycline improves clinical outcomes during cystic fibrosis exacerbations.

Xu X, Abdalla T, Bratcher PE, Jackson PL, Sabbatini G, Wells JM, Lou XY, Quinn R, Blalock JE, Clancy JP, Gaggar A.

Eur Respir J. 2017 Apr 5;49(4). pii: 1601102. doi: 10.1183/13993003.01102-2016. Print 2017 Apr.

50.

Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes.

Shah SR, Rao PN, Sarin SK, Chowdhury A, Bhatia S, Dharamsi R, Goswami BD, Kapoor D, Luaia R, Mehta R, Mukewar S, Prasad VG, Rai RR, Saigal S, Singh D, Trehanpati N, Chen S, Gaggar A, Knox SJ, Subramanian GM, Singh SP, Sood A, Varghese J, Venugopal RV.

Indian J Gastroenterol. 2016 Nov;35(6):469-477. Epub 2016 Nov 15.

PMID:
27844277

Supplemental Content

Loading ...
Support Center